Miller

Home

PI Bio

Miller, Miles , PhD

Miles_miller
Phone:
Email: mmiller29@mgh.harvard.edu

Research

Miles Miller received his A.B. in Chemistry from Princeton University, and his Ph.D. in Biological Engineering from the Massachusetts Institute of Technology (Advisors: Douglas Lauffenburger and Linda Griffith). He trained as a NIH postdoctoral fellow under Dr. Ralph Weissleder at MGH. He specializes in parsing mechanisms of cell signaling and drug action from a quantitative network-level perspective, with training in computational modeling, imaging, nanotechnology, cell signaling biology, and drug delivery.

Selected Publications (from total of 37)

Miller MA
Nanotransfection brings progress that’s more than skin-deep
Sci Transl Med. 2017;9(405):eaao4216
Miller MA, Weissleder R
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior
Adv Drug Deliv Rev. 2017;113:61-86
Conrad C, Dorzweiler K, Miller MA, Lauffenburger DA, Strik H, Bartsch JW
Profiling of metalloprotease activities in cerebrospinal fluids of patients with neoplastic meningitis.
Fluids Barriers CNS. 2017;14(1):22 - PMID: 28806983 - PMCID: PMC5556623
Miller MA
Counting on carbon quantum dots to clear infection
Sci Transl Med. 2017;9(399):eaao0969
Miller MA, Arlauckas S, Weissleder R
Prediction of Anti-cancer Nanotherapy Efficacy by Imaging
Nanotheranostics. 2017;1(3):296-312
Miller MA, Askevold B, Mikula H, Kohler RH, Pirovich D, Weissleder R
Nano-palladium is a cellular catalyst for in vivo chemistry
Nat Commun. 2017;8:15906 - PMID: 28699627 - PMCID: PMC5510178
Miller MA, Weissleder R
Imaging of anticancer drug action in single cells
Nat Rev Cancer. 2017;17:399–414
Miller MA, Chandra R, Cuccarese MF, Pfirschke C, Engblom C, Stapleton S, Adhikary U, Kohler RH, Mohan JF, Pittet MJ, Weissleder R
Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts
Sci Transl Med. 2017;9(392):eaal0225 - PMID: 28566423
Miller MA
Driver mutations take the wheel in invasive yet nonmalignant disease.
Sci Transl Med. 2017;9(393):ePub - PMID: 28592567
Arlauckas SP*, Garris CS*, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
Sci Transl Med. 2017;9(389):eaal3604 - PMID: 28490665 - Cover
Miller MA
Nanoparticles improve economic mileage for CARs.
Sci Transl Med. 2017;9(387):ePub - PMID: 28446684
Conrad C, Miller MA, Bartsch JW, Schlomann U, Lauffenburger DA
Simultaneous Detection of Metalloprotease Activities in Complex Biological Samples Using the PrAMA (Proteolytic Activity Matrix Assay) Method.
Methods Mol Biol. 2017;1574:243-253 - PMID: 28315256
Miller MA
Richer data with personalized GEMs.
Sci Transl Med. 2017;9(381):ePub - PMID: 28298424
Cuccarese MF, Dubach JM, Pfirschke C, Engblom C, Garris C, Miller MA, Pittet MJ, Weissleder R
Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
Nat Commun. 2017;8:14293 - PMID: 28176769 - PMCID: PMC5309815
Miller MA, Sullivan RJ, Lauffenburger DA
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.
Clin Cancer Res. 2016;23(3):623-629 - PMID: 27895032 - PMCID: PMC5290119
15